Skip to main content
Top
Published in: BMC Nephrology 1/2022

01-12-2022 | Metabolic Acidosis | Research article

Lower bicarbonate level is associated with CKD progression and all-cause mortality: a propensity score matching analysis

Authors: Hirotaka Fukasawa, Mai Kaneko, Yuri Uchiyama, Hideo Yasuda, Ryuichi Furuya

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Although metabolic acidosis is known as a potential complication of chronic kidney disease (CKD), there is limited information concerning the association between metabolic acidosis and clinical outcomes.

Methods

Five hundred fifty-two patients referred to renal division of Iwata City Hospital from 2015 to 2017 were included as a retrospective CKD cohort, and finally 178 patients with CKD stage III or IV and 20 to 80 years of age were analyzed. We examined the association between serum bicarbonate (HCO3) levels and clinical outcomes using Kaplan-Meier methods after the matching of baseline characteristics by propensity scores.

Results

Of 178 patients with CKD, patients with lower HCO3 levels (N = 94), as compared with patients with higher HCO3 levels (N = 84), were more likely to be male (P < 0.05), had more severe CKD stages (P < 0.05), more frequent use of renin-angiotensin system inhibitor (P < 0.05) or uric acid lowering agent (P < 0.001), heavier body weight (P < 0.001) and lower estimated glomerular filtration rate (P < 0.05). In Kaplan-Meier analysis after propensity score matching, the incidence of composite outcome as the doubling of serum creatinine level from baseline, end-stage kidney disease requiring the initiation of dialysis, or death from any causes was significantly fewer in the higher HCO3 group than the lower HCO3 group (N = 57 each group, P = 0.016).

Conclusions

Lower HCO3 level is significantly associated with the doubling of serum creatinine level, end-stage kidney disease or all-cause mortality in patients with CKD.

Trial registration

This study was registered with the Clinical Trial Registry of the University Hospital Medical Information Network (http://​www.​umin.​ac.​jp/​, study number: UMIN000044861).
Literature
2.
3.
go back to reference Goraya N, Wesson DE. Management of the Metabolic Acidosis of chronic kidney disease. Adv Chronic Kidney Dis. 2017;24:298–304.CrossRefPubMed Goraya N, Wesson DE. Management of the Metabolic Acidosis of chronic kidney disease. Adv Chronic Kidney Dis. 2017;24:298–304.CrossRefPubMed
4.
go back to reference Yaqoob MM. Acidosis and progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:489–92.CrossRefPubMed Yaqoob MM. Acidosis and progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:489–92.CrossRefPubMed
5.
go back to reference Shah SN, Abramowitz M, Hostetter TH, Melamed ML. Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis. 2009;54:270–7.CrossRefPubMedPubMedCentral Shah SN, Abramowitz M, Hostetter TH, Melamed ML. Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis. 2009;54:270–7.CrossRefPubMedPubMedCentral
6.
go back to reference Raphael KL, Wei G, Baird BC, Greene T, Beddhu S. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int. 2011;79:356–62.CrossRefPubMed Raphael KL, Wei G, Baird BC, Greene T, Beddhu S. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int. 2011;79:356–62.CrossRefPubMed
7.
go back to reference Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, et al. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2013;62:670–8.CrossRefPubMedPubMedCentral Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, et al. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2013;62:670–8.CrossRefPubMedPubMedCentral
8.
go back to reference Jeong J, Kwon SK, Kim HY. Effect of bicarbonate supplementation on renal function and nutritional indices in predialysis advanced chronic kidney disease. Electrolyte Blood Press. 2014;12:80–7.CrossRefPubMedPubMedCentral Jeong J, Kwon SK, Kim HY. Effect of bicarbonate supplementation on renal function and nutritional indices in predialysis advanced chronic kidney disease. Electrolyte Blood Press. 2014;12:80–7.CrossRefPubMedPubMedCentral
9.
go back to reference Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int. 2014;86:1031–8.CrossRefPubMed Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int. 2014;86:1031–8.CrossRefPubMed
10.
go back to reference Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, et al. Sodium bicarbonate supplementation and urinary TGF-beta1 in nonacidotic diabetic kidney disease: a randomized, controlled trial. Clin J Am Soc Nephrol. 2020;15:200–8.CrossRefPubMedPubMedCentral Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, et al. Sodium bicarbonate supplementation and urinary TGF-beta1 in nonacidotic diabetic kidney disease: a randomized, controlled trial. Clin J Am Soc Nephrol. 2020;15:200–8.CrossRefPubMedPubMedCentral
11.
go back to reference Improving Global Outcomes (KDIGO) CKD Work Group. KDOGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kiney Int Suppl. 2013;3:1–150.CrossRef Improving Global Outcomes (KDIGO) CKD Work Group. KDOGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kiney Int Suppl. 2013;3:1–150.CrossRef
12.
go back to reference Wesson DE, Buysse JM, Bushinsky DA. Mechanisms of metabolic acidosis-induced kidney injury in chronic kidney disease. J Am Soc Nephrol. 2020;31:469–82.CrossRefPubMedPubMedCentral Wesson DE, Buysse JM, Bushinsky DA. Mechanisms of metabolic acidosis-induced kidney injury in chronic kidney disease. J Am Soc Nephrol. 2020;31:469–82.CrossRefPubMedPubMedCentral
13.
go back to reference Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators JAMA. 1996;276:889–97.PubMed Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators JAMA. 1996;276:889–97.PubMed
14.
go back to reference Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T, et al. Targeting uric acid and the inhibition of progression to end-stage renal disease--a propensity score analysis. PLoS One. 2015;10:e0145506.CrossRefPubMedPubMedCentral Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T, et al. Targeting uric acid and the inhibition of progression to end-stage renal disease--a propensity score analysis. PLoS One. 2015;10:e0145506.CrossRefPubMedPubMedCentral
15.
go back to reference Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE. Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney Int. 2008;73:192–9.CrossRefPubMed Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE. Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney Int. 2008;73:192–9.CrossRefPubMed
16.
go back to reference Wesson DE, Simoni J. Increased tissue acid mediates a progressive decline in the glomerular filtration rate of animals with reduced nephron mass. Kidney Int. 2009;75:929–35.CrossRefPubMed Wesson DE, Simoni J. Increased tissue acid mediates a progressive decline in the glomerular filtration rate of animals with reduced nephron mass. Kidney Int. 2009;75:929–35.CrossRefPubMed
17.
go back to reference de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20:2075–84.CrossRefPubMedPubMedCentral de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20:2075–84.CrossRefPubMedPubMedCentral
18.
go back to reference Nath KA, Hostetter MK, Hostetter TH. Increased ammoniagenesis as a determinant of progressive renal injury. Am J Kidney Dis. 1991;17:654–7.CrossRefPubMed Nath KA, Hostetter MK, Hostetter TH. Increased ammoniagenesis as a determinant of progressive renal injury. Am J Kidney Dis. 1991;17:654–7.CrossRefPubMed
19.
go back to reference Wesson DE, Simoni J, Broglio K, Sheather S. Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol. 2011;300:F830–7.CrossRefPubMed Wesson DE, Simoni J, Broglio K, Sheather S. Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol. 2011;300:F830–7.CrossRefPubMed
20.
go back to reference Wesson DE, Jo CH, Simoni J. Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR. Nephrol Dial Transplant. 2015;30:762–70.CrossRefPubMed Wesson DE, Jo CH, Simoni J. Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR. Nephrol Dial Transplant. 2015;30:762–70.CrossRefPubMed
21.
go back to reference Halperin ML, Ethier JH, Kamel KS. Ammonium excretion in chronic metabolic acidosis: benefits and risks. Am J Kidney Dis. 1989;14:267–71.CrossRefPubMed Halperin ML, Ethier JH, Kamel KS. Ammonium excretion in chronic metabolic acidosis: benefits and risks. Am J Kidney Dis. 1989;14:267–71.CrossRefPubMed
22.
go back to reference Raphael KL. Metabolic acidosis and subclinical metabolic acidosis in CKD. J Am Soc Nephrol. 2018;29:376–82.CrossRefPubMed Raphael KL. Metabolic acidosis and subclinical metabolic acidosis in CKD. J Am Soc Nephrol. 2018;29:376–82.CrossRefPubMed
23.
go back to reference Goraya N, Simoni J, Sager LN, Mamun A, Madias NE, Wesson DE. Urine citrate excretion identifies changes in acid retention as eGFR declines in patients with chronic kidney disease. Am J Physiol Renal Physiol. 2019;317:F502–F11.CrossRefPubMedPubMedCentral Goraya N, Simoni J, Sager LN, Mamun A, Madias NE, Wesson DE. Urine citrate excretion identifies changes in acid retention as eGFR declines in patients with chronic kidney disease. Am J Physiol Renal Physiol. 2019;317:F502–F11.CrossRefPubMedPubMedCentral
24.
go back to reference Goraya N, Simoni J, Sager LN, Madias NE, Wesson DE. Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis. Kidney Int. 2019;95:1190–6.CrossRefPubMed Goraya N, Simoni J, Sager LN, Madias NE, Wesson DE. Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis. Kidney Int. 2019;95:1190–6.CrossRefPubMed
25.
go back to reference Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Wehbe E, Raina R, et al. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:2395–402.CrossRefPubMedPubMedCentral Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Wehbe E, Raina R, et al. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:2395–402.CrossRefPubMedPubMedCentral
26.
go back to reference Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010;78:303–9.CrossRefPubMed Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010;78:303–9.CrossRefPubMed
27.
go back to reference Morooka H, Yamamoto J, Tanaka A, Inaguma D, Maruyama S. Relationship between mortality and use of sodium bicarbonate at the time of dialysis initiation: a prospective observational study. BMC Nephrol. 2021;22:118.CrossRefPubMedPubMedCentral Morooka H, Yamamoto J, Tanaka A, Inaguma D, Maruyama S. Relationship between mortality and use of sodium bicarbonate at the time of dialysis initiation: a prospective observational study. BMC Nephrol. 2021;22:118.CrossRefPubMedPubMedCentral
28.
go back to reference Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45:275–80.CrossRefPubMed Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45:275–80.CrossRefPubMed
29.
go back to reference Rajan V, Mitch WE. Ubiquitin, proteasomes and proteolytic mechanisms activated by kidney disease. Biochim Biophys Acta. 1782;2008:795–9. Rajan V, Mitch WE. Ubiquitin, proteasomes and proteolytic mechanisms activated by kidney disease. Biochim Biophys Acta. 1782;2008:795–9.
Metadata
Title
Lower bicarbonate level is associated with CKD progression and all-cause mortality: a propensity score matching analysis
Authors
Hirotaka Fukasawa
Mai Kaneko
Yuri Uchiyama
Hideo Yasuda
Ryuichi Furuya
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02712-y

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.